Trospium chloride in patients with neurogenic detrusor overactivity: Is dose titration of benefit to the patients?

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 12, 2006, Pages 623-632

  Menarini, M ^a   Del Popolo, G ^b   Di Benedetto, P ^c   Haselmann, J ^d   Bodeker R H ^e   Schwantes, Ulrich ^d   Madersbacher, H ^f   Sember, Mario Eduardo ^g   Bersch, Ulf ^h   Chiang, Humberto ⁱ   Dörsam, Joachim ^j   Nützel, Reinhold ^k   Strasser, Felix ^l   Kiss, Gustav ^f  

^a Montecatone Rehabilitation Institute   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Ospedale Santorio   (Italy)

^d Dr R Pfleger GmbH   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f Neuro Urologische Ambulanz   (Austria)

^g Buenos Aires   (Argentina)

^h SWISS PARAPLEGIC RESEARCH   (Switzerland)

ⁱ Mutual de Seguridad Hospital   (Chile)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k Klinikum Hohe Warte   (Germany)

^l Rehabilitationszentrum Bad Häring   (Austria)

more..

Author keywords

Clinical study; Dose titration; Neurogenic detrusor overactivity; Trospium

Indexed keywords

TROSPIUM CHLORIDE;

ADULT; ARTICLE; BLADDER COMPLIANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; GASTROINTESTINAL DISEASE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; URODYNAMICS; XEROSTOMIA;

EID: 33845388576     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44623     Document Type: Article

References (41)

1. Andersson KE, Appell R, Awad S et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S et al: Incontinence. 2nd International Consultation on Incontinence. Plymouth: Health Publication; 2002. pp. 479-511.
2. Andersson KE, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S et al.: Incontinence. 3rd International Consultation on Incontinence. Plymouth: Health Publication; 2005. pp. 809-855.
3. Andersson KE, Schröder A. Veränderungen der Muskarinrezeptoren der alternden Harnblase. Urologe. 2004; A43: 552-556.
4. Bennett N, O'Leary M, Patel AS et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004; 171: 749-751.
5. Braun PM, Jünemann KP. Zystometrie. In: Palmtag H, Goepel M, Heidler H (eds). Urodynamik. Berlin: Springer; 2004. pp. 93-94.
6. Breuel HP, Mürtz G, Bondy S et al. Safety and tolerance of trospium chloride in the high dose range. Drug Res. 1993; 43: 461-464.
7. Chapple CR, Arano P, Bosch JLHR et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Br J Urol. 2004a; 93: 71-77.
8. Chapple CR, Rechberger T, Al-Shukri P et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol. 2004b; 93: 303-330.
9. Clemett D, Jarvis B. Tolterodine. A review of its use in the treatment of overactive bladder. Drugs Aging. 2001; 18: 277-304.
10. Creasey GH. Managing bladder, bowel and sexual function after spinal cord injury. In: Rushton DN (ed). Handbook of Neurourology. New York: Marcel Dekker; 1994. pp. 233-251.
11. Davila GW, Daugherty CA, Sanders SW et al. A short-term, multicenter, randomised double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001; 166: 140-145.
12. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005; 44: 701-720.
13. Flood HD, Ritchey ML, Bloom DA et al. Outcome of reflux in children with myelodysplasia managed by bladder pressure monitoring. J Urol. 1994; 152: 1574-1577.
14. Fröhlich G, Bulitta M, Strösser W. Trospium chloride in patients with detrusor overactivity. Meta-anaylsis of placebo-controlled, randomized, double-blind, multicenter clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther. 2002; 40: 295-303.
15. Füsgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000; 38: 223-234.
16. Hedge SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies. Curr Opin Invest Drugs. 2004; 5: 40-49.
17. Höfner K, Halaska M, Primus G et al. Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge-syndrome: a double-blind, controlled, multicentre clinical trial. Neurourol Urodyn. 2000; 19: 487-488.
18. Homma Y, Batista J, Bauer S et al. Urodynamics. In: Abrams P, Cardozo L, Khoury S et al (eds). Incontinence. 2nd International Consultation on Incontinence. Plymouth: Health Publication; 2002. pp. 317-372.
19. ICH Topic E4. Dose response information to support drug registration. CPMP/ICH/378/95, ICH-Technical Coordination, London; 1994. pp. 1-11.
20. Jünemann KP, Füsgen I. Placebo-controlled, randomised, double-blind, multicentre clinical trial on the efficacy and tolerability of 1 × 40 mg and 2 × 40 mg trospium chloride daily for 3 weeks in patients with urge-syndrome. Neurourol Urodyn. 1999; 18: 375-376.
21. Jünemann KP, Füsgen I, Svetlana T. Trospium chloride 40 mg - a placebo-controlled, randomised, double-blind clinical trial on the efficacy and tolerability for 3 weeks in patients with urge-syndrome. Eur Urol. 2000; 37: 84.
22. Kelleher CJ. Economic and social impact of OAB. Eur Urol. 2002; Suppl 1: 11-16.
23. Luscombe FA. Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment. Rev Contemp Pharmacother. 2000; 11: 43-62.
24. Madersbacher H, Stöhrer M, Richter R et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol. 1991; 75: 452-456.
25. Massey JA, Abrams P. Dose titration in clinical trials. An example using emepronium carrageenate in detrusor instability. Br J Urol. 1986; 58: 125-128.
26. McGuire EJ, Ohl DA, Noll F. Die Pathophysiologie der neurogenen Blasenstörungen. In: Stöhrer M, Madersbacher H, Palmtag H (eds). Neurogene Blasenfunktionsstörung, Neurogene Sexualstörung. Berlin: Springer; 1997. pp. 5-17.
27. Miller KL, DuBeau CE, Bergmann MA et al. Dose titration key to oxybutynin efficacy for geriatric incontinence even for DHIC. Neurourol Urodyn. 2000; 19: 538-539.
28. Osca-Garcia JM, Martinez Agullo E, Conejero Sugranes J et al. Trospiumchlorid versus Oxybutynin in der Behandlung der hyperaktiven Blase - eine randomisierte doppelblinde Studie. Jatros Urol. 1997; 13: 35-39.
29. Rentzhog L, Stanton SL, Cardozo L et al. Efficacy and safety of tolterodine in patients with detrusor instability. A dose-ranging study. Br J Urol. 1998; 81: 42-48.
30. Rudy D, Cline K, Goldberg K et al. A multicenter, randomised, placebo-controlled trial of trospium chloride in overactive bladder patients. Neurourol Urodyn. 2004; 23: 600-601.
31. Schröder S, Jetter A, Zaigler M, Weyhenmeyer R, Krumbiegel G, Wächter W, Fuhr U. Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. Int J Clin Pharmacol Ther. 2004; 42: 543-549.
32. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia - chances for improvement of therapy. Int J Clin Pharamcol Ther. 1999; 37: 209-218.
33. Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med. 2006; 119 (3 Suppl 1): 9-15.
34. Steers W, Corcos J, Foote J et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. Br J Urol. 2005; 95: 580-586.
35. Stöhrer M, Bersch U, Göcking K et al. Dose finding study for treatment of detrusor hyperreflexia by trospium chloride. Iguassu, Brazil: 37th Ann Meet Int Soc Paraplegia; 1998. pp. 18-20.
36. Stöhrer M, Goepel M, Kondo A et al. The standardization of terminology in neurogenic lower urinary tract dysfunction. With suggestions for diagnostic procedures. Neurourol Urodyn. 1999; 18: 139-158.
37. Stöhrer M, Castro-Diaz D, Chartier-Kastler E et al. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology www.uroweb.org 2003; pp. 21-40.
38. Tubaro, A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004; 64 (Suppl 6A): 2-6.
39. Ulshöfer B, Bihr AM, Bödeker RH et al. Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence. Clin Drug Invest. 2001; 21: 563-569.
40. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002; 60 (Suppl 5A): 7-12.
41. Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004; 171: 2311-2315.